Across the globe, the vital lifeline of blood, indispensable for saving lives and improving health, remains unevenly accessible and safe. This comprehensive overview, drawing on data up to 2018 from the Global Database on Blood Safety, reveals a landscape of both progress and persistent disparities in blood collection, testing, processing, and clinical transfusion services worldwide. It charts the journey of nations in their endeavor to establish nationally coordinated and well-managed blood transfusion systems, a cornerstone for universal health coverage.
Between 2008 and 2018, a significant and heartening trend emerged: an increase of 10.7 million blood donations from voluntary, unpaid donors, particularly notable within low- and middle-income countries. This shift towards altruistic donation is crucial, as it underpins the safety and sustainability of blood supplies. Yet, the reliance on family/replacement or paid donors still persists in many regions, with over 50% of the blood supply in 54 countries stemming from these sources, highlighting a continued vulnerability in the system.
The stark reality of inequality in access to blood is undeniable. High-income countries, representing only 16% of the world's population, collect a disproportionate 40% of global blood donations. Their donation rates stand at 31.5 donations per 1000 people, a stark contrast to the 5.0 donations per 1000 people in low-income countries. Furthermore, the demographic of recipients varies dramatically; in low-income settings, up to 54% of transfusions are administered to children under five, while in high-income nations, the elderly, those over 60, constitute the largest group, accounting for up to 76% of all transfusions.
Ensuring the safety of every unit of blood remains a paramount challenge. While high-income countries achieve near-universal screening of donated blood for transfusion-transmissible infections, with 99.8% of donations screened following quality procedures, this figure drops sharply to 83% in lower-middle-income countries and 76% in low-income nations. This gap exposes millions to preventable risks, underscoring the urgent need for enhanced infrastructure and quality assurance mechanisms across all regions.
Beyond whole blood, the availability of plasma-derived medicinal products (PDMPs) presents another critical area of disparity. Only 56 out of 171 reporting countries produce PDMPs through the fractionation of locally collected plasma. A staggering 91 countries reported importing all their PDMPs, while 16 countries indicated no use of these essential products during the reporting period. The volume of plasma collected for fractionation also varies immensely, from 0.1 to 52.6 liters per 1000 population, revealing significant inequities in the ability to meet patient needs for these specialized treatments.
The foundation of a robust blood system lies in strong national policies and legislative frameworks. While 73% of reporting countries had a national blood policy in 2018, and 66% had specific legislation covering blood transfusion safety and quality, these figures reveal gaps, particularly in low-income countries where only 39% possess such legislation. These frameworks are essential for promoting uniform standards and ensuring consistency in the quality and safety of blood and blood products from donor to recipient.
The journey towards universal access to safe, effective, and quality-assured blood products is ongoing. Progress has been made in increasing voluntary donations and establishing national services, yet significant work remains to address the profound inequities in availability, safety, and access to specialized blood components. Continued investment, policy development, and international collaboration are vital to fortify blood transfusion services globally, ensuring that every patient in need receives the timely and safe blood they require.
